On Monday, H.C. Wainwright maintained a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a steady price target of $400.00. The firm's analyst highlighted Alnylam's third-quarter financials, which aligned with expectations, reporting net product revenues of $420 million.
This figure slightly exceeded the firm's forecast of $416 million and surpassed the FactSet pre-earnings consensus of $418 million. Specifically, revenues from transthyretin amyloidosis (ATTR) treatments AMVUTTRA and ONPATTRO totaled $309 million, while revenues from the ultra-rare disease treatments GIVLAARI and OXLUMO reached $111 million.
Alnylam reiterated its net product revenue guidance for 2024, projecting between $1.575 billion and $1.650 billion. This guidance aligns closely with H.C. Wainwright's estimate of $1.64 billion and the FactSet consensus of $1.63 billion. The company has also recently submitted regulatory filings for AMVUTTRA in ATTR-CM to the FDA and European Medicines Agency, anticipating a potential U.S. launch in the second half of 2025, followed by international market introductions.
The company has plans to present data from its ATTR franchise and its hypertension program zilebesiran at the American Heart Association Scientific Sessions scheduled from November 16-18 in Chicago. Further, Alnylam expects to disclose findings from the ongoing Phase 1 study of ALN-TTRsc04, an investigational treatment for ATTR amyloidosis, at the same event. A detailed Phase 3 development plan for ALN-TTRsc04 is slated for release in the first quarter of 2025.
The analyst expressed high confidence in the FDA approval of AMVUTTRA for ATTR-CM, an indication with the potential to generate over $5 billion in annual revenue. This optimism underpins the firm's reiterated Buy rating and $400 price target on Alnylam Pharmaceuticals shares.
In other recent news, Alnylam Pharmaceuticals has reported a significant 34% year-over-year increase in global net product revenue for Q3 2024, totaling $420 million. The TTR franchise, including treatments like ONPATTRO and AMVUTTRA, played a crucial role in this growth, generating $309 million. Furthermore, Alnylam revealed advancements in its pipeline, specifically in treatments for Alzheimer's and Huntington's diseases, and reaffirmed its revenue guidance for 2024.
The company also highlighted its clinical development pipeline's progress, aiming to double it by the end of 2025. Alnylam is preparing for the U.S. and EU launch of AMVUTTRA in 2025, with increased commercial investments anticipated. Despite a decrease in collaboration revenues to $57 million due to the absence of prior upfront payments, royalty revenues increased to $23 million, and the gross margin on product sales improved to 80%.
However, Alnylam has ceased the ALN-KHK program for type 2 diabetes to reallocate resources more effectively. In response to recent developments, Alnylam remains open to business development opportunities that enhance their platform.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Alnylam Pharmaceuticals' financial position and market performance. The company's market capitalization stands at $35.33 billion, reflecting its significant presence in the biotechnology sector. Alnylam's revenue for the last twelve months as of Q3 2024 reached $2.09 billion, with a notable revenue growth of 21.54% over the same period. This aligns with the company's strong product revenue performance mentioned in the article.
InvestingPro Tips highlight that Alnylam has seen a large price uptick over the last six months, with data showing a remarkable 79.81% price total return in that timeframe. This surge in stock price could be attributed to investor optimism surrounding the company's product pipeline and potential FDA approvals, as discussed in the article.
Another relevant InvestingPro Tip indicates that analysts have revised their earnings upwards for the upcoming period, which may reflect positive expectations for Alnylam's future performance, particularly in light of the anticipated AMVUTTRA launch for ATTR-CM in 2025.
For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips for Alnylam Pharmaceuticals, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.